Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
AHNAK nucleoprotein 2
(
AHNAK2
) has been emerged as a crucial protein for neuroblast differentiation and cell migration, thereby involving in the development of various cancers. However, the specific molecular mechanism of
AHNAK2
in lung adenocarcinoma is inconclusive. By accessing to the Oncomine dataset and GEPIA website, a higher expression level of
AHNAK2
was observed in lung adenocarcinoma tissue samples. Overall survival (OS) curve plotted by Kaplan-Meier method showed that up-regulation of
AHNAK2
was related with poor prognosis of lung adenocarcinoma patients. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis and western blot were conducted to examine the expression level of genes in lung adenocarcinoma cells. Through functional
in vitro
experiments, cell proliferation, migration and invasion were all suppressed after
AHNAK2
knockdown using Cell counting kit-8 (CCK-8) assay, wound-healing and transwell analysis. Reduction of
AHNAK2
decreased the apoptosis rate using flow cytometry analysis. Moreover, the key markers of MAPK pathway, p-
MEK
, p-ERK and p-P90RSK were decreased due to the transfection of si-
AHNAK2
in A549 cells. U0126, a
MEK
inhibitor, showed the similar effects on MAPK-related protein levels with si-
AHNAK2
. To sum up,
AHNAK2
is significantly increased in lung adenocarcinoma and plays a carcinogenic role by activating the MAPK signaling pathway, providing a novel insight and raising possibility for lung adenocarcinoma treatment.
...
PMID:Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma. 3300 Jun 78